CA2962157A1 - Agents de liaison cd133 et utilisations associees - Google Patents

Agents de liaison cd133 et utilisations associees Download PDF

Info

Publication number: CA2962157A1
Authority: CA; Canada
Prior art keywords: seq; amino acid; binding; acid sequence; antibody
Prior art date: 2016-10-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CA2962157A

Other languages

English (en)

Inventor

Jason MOFFAT

Jarrett ADAMS

Guohua Pan

Sachdev Sidhu

Rashida WILLIAMS

Xiaoyu Zhang

Sheila SINGH

Chitra VENUGOPAL

Parvez VORA

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

McMaster University

University of Toronto

Original Assignee

McMaster University

University of Toronto

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-10-19

Filing date

2017-03-16

Publication date

2018-04-19

2017-03-16 Application filed by McMaster University, University of Toronto filed Critical McMaster University

2018-04-19 Publication of CA2962157A1 publication Critical patent/CA2962157A1/fr

Status Pending legal-status Critical Current

Links

239000011230 binding agent Substances 0.000 title claims abstract description 229
206010028980 Neoplasm Diseases 0.000 claims abstract description 127
101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims abstract description 101
201000011510 cancer Diseases 0.000 claims abstract description 95
102100040120 Prominin-1 Human genes 0.000 claims abstract description 62
230000014509 gene expression Effects 0.000 claims abstract description 34
230000008685 targeting Effects 0.000 claims abstract description 23
230000001413 cellular effect Effects 0.000 claims abstract description 20
210000004027 cell Anatomy 0.000 claims description 341
125000003275 alpha amino acid group Chemical group 0.000 claims description 223
230000027455 binding Effects 0.000 claims description 201
208000005017 glioblastoma Diseases 0.000 claims description 82
108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 64
210000001744 T-lymphocyte Anatomy 0.000 claims description 61
239000000427 antigen Substances 0.000 claims description 47
108091007433 antigens Proteins 0.000 claims description 47
102000036639 antigens Human genes 0.000 claims description 47
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 45
206010009944 Colon cancer Diseases 0.000 claims description 41
229940127121 immunoconjugate Drugs 0.000 claims description 39
239000008194 pharmaceutical composition Substances 0.000 claims description 39
102000044752 human PROM1 Human genes 0.000 claims description 38
108010047041 Complementarity Determining Regions Proteins 0.000 claims description 36
239000003795 chemical substances by application Substances 0.000 claims description 33
208000000172 Medulloblastoma Diseases 0.000 claims description 30
208000003174 Brain Neoplasms Diseases 0.000 claims description 29
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 27
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 27
201000002528 pancreatic cancer Diseases 0.000 claims description 27
208000008443 pancreatic carcinoma Diseases 0.000 claims description 27
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 26
230000011664 signaling Effects 0.000 claims description 22
208000029742 colonic neoplasm Diseases 0.000 claims description 19
206010060862 Prostate cancer Diseases 0.000 claims description 18
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 18
210000004556 brain Anatomy 0.000 claims description 17
239000012636 effector Substances 0.000 claims description 16
239000012634 fragment Substances 0.000 claims description 16
206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 15
208000021039 metastatic melanoma Diseases 0.000 claims description 15
210000002307 prostate Anatomy 0.000 claims description 15
238000001514 detection method Methods 0.000 claims description 11
210000002865 immune cell Anatomy 0.000 claims description 10
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 9
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 9
239000002246 antineoplastic agent Substances 0.000 claims description 9
102000005962 receptors Human genes 0.000 claims description 9
239000003053 toxin Substances 0.000 claims description 8
231100000765 toxin Toxicity 0.000 claims description 8
108700012359 toxins Proteins 0.000 claims description 8
108020003175 receptors Proteins 0.000 claims description 7
229940034982 antineoplastic agent Drugs 0.000 claims description 6
230000003247 decreasing effect Effects 0.000 abstract description 4
238000000034 method Methods 0.000 description 61
108090000765 processed proteins & peptides Proteins 0.000 description 50
108090000623 proteins and genes Proteins 0.000 description 48
150000007523 nucleic acids Chemical class 0.000 description 40
102000004196 processed proteins & peptides Human genes 0.000 description 39
102000004169 proteins and genes Human genes 0.000 description 38
235000018102 proteins Nutrition 0.000 description 37
229920001184 polypeptide Polymers 0.000 description 35
102000039446 nucleic acids Human genes 0.000 description 34
108020004707 nucleic acids Proteins 0.000 description 34
108091028043 Nucleic acid sequence Proteins 0.000 description 33
208000001333 Colorectal Neoplasms Diseases 0.000 description 22
238000002965 ELISA Methods 0.000 description 22
238000000684 flow cytometry Methods 0.000 description 21
238000011282 treatment Methods 0.000 description 20
239000003814 drug Substances 0.000 description 18
125000000539 amino acid group Chemical group 0.000 description 17
241001465754 Metazoa Species 0.000 description 16
239000000523 sample Substances 0.000 description 16
235000001014 amino acid Nutrition 0.000 description 15
238000003556 assay Methods 0.000 description 14
238000010494 dissociation reaction Methods 0.000 description 14
230000005593 dissociations Effects 0.000 description 14
238000001262 western blot Methods 0.000 description 13
150000001413 amino acids Chemical class 0.000 description 12
238000009396 hybridization Methods 0.000 description 12
239000013598 vector Substances 0.000 description 12
108060003951 Immunoglobulin Proteins 0.000 description 11
102000018358 immunoglobulin Human genes 0.000 description 11
239000002773 nucleotide Substances 0.000 description 11
125000003729 nucleotide group Chemical group 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
229940124597 therapeutic agent Drugs 0.000 description 11
108020004414 DNA Proteins 0.000 description 10
241000699670 Mus sp. Species 0.000 description 10
238000010166 immunofluorescence Methods 0.000 description 10
238000012163 sequencing technique Methods 0.000 description 10
230000004083 survival effect Effects 0.000 description 10
239000012130 whole-cell lysate Substances 0.000 description 10
239000004480 active ingredient Substances 0.000 description 9
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 8
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 8
230000000295 complement effect Effects 0.000 description 8
230000006870 function Effects 0.000 description 8
210000004408 hybridoma Anatomy 0.000 description 8
239000003550 marker Substances 0.000 description 8
239000000203 mixture Substances 0.000 description 8
238000011160 research Methods 0.000 description 8
210000004881 tumor cell Anatomy 0.000 description 8
241001529936 Murinae Species 0.000 description 7
238000013459 approach Methods 0.000 description 7
210000005103 brain tumor initiating cell Anatomy 0.000 description 7
230000030833 cell death Effects 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000012642 immune effector Substances 0.000 description 7
229940121354 immunomodulator Drugs 0.000 description 7
210000000130 stem cell Anatomy 0.000 description 7
102100021277 Beta-secretase 2 Human genes 0.000 description 6
101710150190 Beta-secretase 2 Proteins 0.000 description 6
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 6
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000003993 interaction Effects 0.000 description 6
230000003834 intracellular effect Effects 0.000 description 6
-1 scIgG) Proteins 0.000 description 6
238000010186 staining Methods 0.000 description 6
230000004913 activation Effects 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
239000012528 membrane Substances 0.000 description 5
230000001394 metastastic effect Effects 0.000 description 5
206010061289 metastatic neoplasm Diseases 0.000 description 5
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000009738 saturating Methods 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
238000012360 testing method Methods 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 4
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 4
101710135898 Myc proto-oncogene protein Proteins 0.000 description 4
102100038895 Myc proto-oncogene protein Human genes 0.000 description 4
125000000729 N-terminal amino-acid group Chemical group 0.000 description 4
101710150448 Transcriptional regulator Myc Proteins 0.000 description 4
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000000975 dye Substances 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000010185 immunofluorescence analysis Methods 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
210000000822 natural killer cell Anatomy 0.000 description 4
238000002823 phage display Methods 0.000 description 4
230000009467 reduction Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
108091035707 Consensus sequence Proteins 0.000 description 3
102100025137 Early activation antigen CD69 Human genes 0.000 description 3
101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 3
101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
206010058467 Lung neoplasm malignant Diseases 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
238000011579 SCID mouse model Methods 0.000 description 3
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 3
208000005718 Stomach Neoplasms Diseases 0.000 description 3
238000007792 addition Methods 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
239000013592 cell lysate Substances 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000010276 construction Methods 0.000 description 3
229940127089 cytotoxic agent Drugs 0.000 description 3
238000002784 cytotoxicity assay Methods 0.000 description 3
231100000263 cytotoxicity test Toxicity 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000000539 dimer Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
230000009977 dual effect Effects 0.000 description 3
206010017758 gastric cancer Diseases 0.000 description 3
201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
229940072221 immunoglobulins Drugs 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
208000014018 liver neoplasm Diseases 0.000 description 3
201000005202 lung cancer Diseases 0.000 description 3
208000020816 lung neoplasm Diseases 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
201000001441 melanoma Diseases 0.000 description 3
239000013641 positive control Substances 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
238000013207 serial dilution Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
229910001415 sodium ion Inorganic materials 0.000 description 3
239000000243 solution Substances 0.000 description 3
201000011549 stomach cancer Diseases 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000003827 upregulation Effects 0.000 description 3
238000010200 validation analysis Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
238000011357 CAR T-cell therapy Methods 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
238000001712 DNA sequencing Methods 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
239000002033 PVDF binder Substances 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
241000700159 Rattus Species 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
108010039491 Ricin Proteins 0.000 description 2
108010084592 Saporins Proteins 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
229940127174 UCHT1 Drugs 0.000 description 2
102000013814 Wnt Human genes 0.000 description 2
108050003627 Wnt Proteins 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
230000006023 anti-tumor response Effects 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000012830 cancer therapeutic Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
239000002254 cytotoxic agent Substances 0.000 description 2
231100000599 cytotoxic agent Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
238000009510 drug design Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
230000004547 gene signature Effects 0.000 description 2
230000012010 growth Effects 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
229940124452 immunizing agent Drugs 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000007917 intracranial administration Methods 0.000 description 2
238000005304 joining Methods 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
201000007270 liver cancer Diseases 0.000 description 2
238000011068 loading method Methods 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000006166 lysate Substances 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
239000013642 negative control Substances 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
230000000174 oncolytic effect Effects 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000013610 patient sample Substances 0.000 description 2
239000000816 peptidomimetic Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000007423 screening assay Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
241000894007 species Species 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
108091005703 transmembrane proteins Proteins 0.000 description 2
102000035160 transmembrane proteins Human genes 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 1
VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
102000005908 AC133 Antigen Human genes 0.000 description 1
108010005465 AC133 Antigen Proteins 0.000 description 1
108010066676 Abrin Proteins 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108091023037 Aptamer Proteins 0.000 description 1
101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
241000282817 Bovidae Species 0.000 description 1
102100027207 CD27 antigen Human genes 0.000 description 1
101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
108010060123 Conjugate Vaccines Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
108700032819 Croton tiglium crotin II Proteins 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
108091008102 DNA aptamers Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
101150029707 ERBB2 gene Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010055196 EphA2 Receptor Proteins 0.000 description 1
102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
101710082714 Exotoxin A Proteins 0.000 description 1
108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
101001068011 Homo sapiens Hydroxyacylglutathione hydrolase-like protein Proteins 0.000 description 1
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
101000634835 Homo sapiens M1-specific T cell receptor alpha chain Proteins 0.000 description 1
101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
101000634836 Homo sapiens T cell receptor alpha chain MC.7.G5 Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
102100034468 Hydroxyacylglutathione hydrolase-like protein Human genes 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102100029450 M1-specific T cell receptor alpha chain Human genes 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
244000302512 Momordica charantia Species 0.000 description 1
235000009811 Momordica charantia Nutrition 0.000 description 1
102100034256 Mucin-1 Human genes 0.000 description 1
108010008707 Mucin-1 Proteins 0.000 description 1
101100170937 Mus musculus Dnmt1 gene Proteins 0.000 description 1
WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 description 1
238000011789 NOD SCID mouse Methods 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229920002123 Pentastarch Polymers 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108010079855 Peptide Aptamers Proteins 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
108091008103 RNA aptamers Proteins 0.000 description 1
PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
240000003946 Saponaria officinalis Species 0.000 description 1
108010003723 Single-Domain Antibodies Proteins 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
240000001866 Vernicia fordii Species 0.000 description 1
230000004156 Wnt signaling pathway Effects 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229940023184 after bite Drugs 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
108010001818 alpha-sarcin Proteins 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000002622 anti-tumorigenesis Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000002902 bimodal effect Effects 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
229960003008 blinatumomab Drugs 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000009087 cell motility Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
239000002458 cell surface marker Substances 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
201000010989 colorectal carcinoma Diseases 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
229940031670 conjugate vaccine Drugs 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
229930191339 dianthin Natural products 0.000 description 1
125000005442 diisocyanate group Chemical group 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
108010028531 enomycin Proteins 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
150000002222 fluorine compounds Chemical class 0.000 description 1
210000001652 frontal lobe Anatomy 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
125000003712 glycosamine group Chemical group 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
150000002463 imidates Chemical class 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000002687 intercalation Effects 0.000 description 1
238000009830 intercalation Methods 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000002324 minimally invasive surgery Methods 0.000 description 1
108010010621 modeccin Proteins 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
108010059074 monomethylauristatin F Proteins 0.000 description 1
238000011228 multimodal treatment Methods 0.000 description 1
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
108091008104 nucleic acid aptamers Proteins 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
108010076042 phenomycin Proteins 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
208000030266 primary brain neoplasm Diseases 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000005180 public health Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000002356 single layer Substances 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000011255 standard chemotherapy Methods 0.000 description 1
238000013517 stratification Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
230000035899 viability Effects 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Cell Biology (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)

CA2962157A 2016-10-19 2017-03-16 Agents de liaison cd133 et utilisations associees Pending CA2962157A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662410162P	2016-10-19	2016-10-19
US62/410162		2016-10-19

Publications (1)

Publication Number	Publication Date
CA2962157A1 true CA2962157A1 (fr)	2018-04-19

Family

ID=61968947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2962157A Pending CA2962157A1 (fr)	2016-10-19	2017-03-16	Agents de liaison cd133 et utilisations associees

Country Status (1)

Country	Link
CA (1)	CA2962157A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109735500A (zh) *	2019-01-25	2019-05-10	苏州茂行生物科技有限公司	一种分泌型靶向cd133的car-t细胞及其制备方法和应用
WO2023133595A2 (fr)	2022-01-10	2023-07-13	Sana Biotechnology, Inc.	Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
WO2024081820A1 (fr)	2022-10-13	2024-04-18	Sana Biotechnology, Inc.	Particules virales ciblant des cellules souches hématopoïétiques
WO2024119157A1 (fr)	2022-12-02	2024-06-06	Sana Biotechnology, Inc.	Particules lipidiques avec cofusogènes et leurs procédés de production et d'utilisation

2017
- 2017-03-16 CA CA2962157A patent/CA2962157A1/fr active Pending

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109735500A (zh) *	2019-01-25	2019-05-10	苏州茂行生物科技有限公司	一种分泌型靶向cd133的car-t细胞及其制备方法和应用
CN109735500B (zh) *	2019-01-25	2023-05-16	苏州茂行生物科技有限公司	一种分泌型靶向cd133的car-t细胞及其制备方法和应用
WO2023133595A2 (fr)	2022-01-10	2023-07-13	Sana Biotechnology, Inc.	Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
WO2024081820A1 (fr)	2022-10-13	2024-04-18	Sana Biotechnology, Inc.	Particules virales ciblant des cellules souches hématopoïétiques
WO2024119157A1 (fr)	2022-12-02	2024-06-06	Sana Biotechnology, Inc.	Particules lipidiques avec cofusogènes et leurs procédés de production et d'utilisation

Legal Events

Date	Code	Title	Description
2023-03-14	EEER	Examination request	Effective date: 20220216
2023-08-01	EEER	Examination request	Effective date: 20220216
2024-03-05	EEER	Examination request	Effective date: 20220216
2024-06-19	EEER	Examination request	Effective date: 20220216

Publication	Publication Date	Title
US20220073640A1 (en)	2022-03-10	Cd133-binding agents and uses thereof
US20210388081A1 (en)	2021-12-16	Antibodies targeting fc receptor-like 5 and methods of use
US20230406941A1 (en)	2023-12-21	Anti-AXL Antagonistic Antibodies
CN106573980B (zh)	2021-05-04	抗axl抗体
CN106573979B (zh)	2021-07-06	抗axl抗体
CN109311997B (zh)	2023-07-18	抗axl拮抗抗体
US11999793B2 (en)	2024-06-04	Therapeutic anti-CD9 antibody
CN110790839B (zh)	2023-05-12	抗pd-1抗体、其抗原结合片段及医药用途
CN112243443B (zh)	2023-03-17	抗trop-2抗体、其抗原结合片段及其医药用途
CA2962157A1 (fr)	2018-04-19	Agents de liaison cd133 et utilisations associees
KR20220030937A (ko)	2022-03-11	항체 및 사용 방법
KR20200074127A (ko)	2020-06-24	항체 및 사용 방법
CA3186256A1 (fr)	2022-02-03	Anticorps anti-lilrb1 et ses utilisations
MOFFAT et al.	0	Patent 2962157 Summary
NZ744187B2 (en)	2021-11-30	Therapeutic anti-cd9 antibody